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Patients were required to have ofﬁce-based systolic blood pressure (BP) 160 mmHg
despite compliance with 3 antihypertensive medications at maximally tolerated
doses. The primary efﬁcacy endpoints were the 6-month reductions in ofﬁce-based
systolic and diastolic BPs, and reductions in systolic and diastolic BP as measured by
24-hour ambulatory monitoring. Acute safety (ie, freedom from renal artery dissection
or perforation requiring stenting or surgery, renal artery infarction or embolus, cere-
brovascular accident, myocardial infarction, or sudden cardiac death at the time of the
procedure) and long-term safety, including renal artery patency and renal function,
were assessed.
Results: Mean baseline ofﬁce BP was 182.418.4/100.114.0 mmHg among
enrolled patients (N¼146; age 58.510.5 years, 61% men, 27.4% with type 2 dia-
betes). No patients experienced any of the prespeciﬁed acute safety events. Among 139
patients with 6 month data, mean ofﬁce BP was reduced to 157.723.8/
89.415.7 mmHg; a reduction of 24.622.3/10.312.9 mmHg (p<0.0001). Mean
baseline ambulatory BP was 153.015.1/87.513.2 mmHg (n¼103); at 6 months it
was reduced by 8.514.6/5.99.2 mmHg (n¼67; p<0.0001). Renal artery patency by
duplex ultrasound at 6 months was 99.1%. Mean estimated glomerular ﬁltration rate
(eGFR) changed -0.916.5 at 6 months, and 11% of patients (15/136) had a
reduction in eGFR >25%. Six-month results for the full cohort of enrolled patients are
expected to be available at the time of presentation.
Conclusions: Primary endpoint results from the REDUCE-HTN trial demonstrate
that the Vessix System is an efﬁcacious method for treating resistant hypertension. No
acute safety endpoint events were observed and 6-month patency and renal function
results are favorable.
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Background: Treatment resistant hypertension (rHTN) is deﬁned as uncontrolled
blood pressure despite use of 3 antihypertensive drugs including a diuretic. The
sympathetic nervous system plays an important role in the pathogenesis of hyper-
tension. The Symplicity renal denervation system uses a percutaneous approach to
deliver low-power radiofrequency energy to interrupt the efferent sympathetic and
afferent renal nerves. Up to 3 year follow-up of pooled patient level data are available to
evaluate renal denervation (RDN) efﬁcacy and safety, including patients with type II
diabetes mellitus (DM).
Methods: The Symplicity HTN-1 and Symplicity HTN-2 prospective, multicenter
trials enrolled rHTN subjects with a systolic BP (SBP) 160 mm Hg; (150 mm
Hg for DM subjects). Subjects remained on their antihypertensive drugs for 6
months after which changes were allowed as clinically indicated. A subset of subjects
in Symplicity HTN-1were consented to 3 years; all subjects randomized to im-
mediate RDN on Symplicity HTN-2 were followed to 3 years post-RDN. Change
from baseline BP was measured at each follow-up and all safety events were
evaluated.
Results: Baseline characteristics of 128 subjects followed through 3 years include
mean age, 58 years; 34% DM, 38% female, and body mass index of 32 kg/m2. Mean
baseline SBP was 175.7  14.1 mm Hg and was reduced by 24.6  22.7 mm Hg at 6
months (p<0.01). This BP reduction was sustained at 3 years with a mean drop of
32.2  19.7 mm Hg (p<0.01). DM and non-DM subjects had similar baseline SBP
and experienced a similar and signiﬁcant reduction in SBP at 3 years (-30.0 mm Hg vs
-33.3 mm Hg, respectively, p<0.001 compared with baseline, p¼0.37 between DM
and non-DM subjects). Procedure-related adverse events included 2 dissections (1
before radiofrequency energy was delivered), and 1 access site hematoma. Serious
adverse events included 6 deaths, 4 renal failure cases (all resolved), and 1 stenosis
requiring stenting.
Conclusions: The data indicates that treatment of rHTN with the Symplicity catheter
provides safe and sustained reductions in SBP through 3 years. The reduction in SBP
was similar in both DM and non DM subjects.*Indicates iMPACT Trial Accepted for Oral PresentationCRT-610
Bipolar Multi-Electrode Balloon Catheter Radiofrequency Renal Denervation with the
Vessix System: Preclinical Safety Evaluation
Gregory J. Wilson,1 Dawn Winsor-Hines,2 Davis Liza,2 Radhika Tunstall,2
Barbara Huibregtse,2 Jeannette Bankes2
1The Research Institute, Division of Physiology and Experimental Medicine, The Hospital
for Sick Children, Toronto, ON, Canada; 2Boston Scientiﬁc Corporation, Natick, MA
Background: A bipolar multi-electrode balloon catheter radiofrequency (RF) renal
denervation system offers advantages of short procedure time and low power to
minimize risk of non-target tissue thermal injury. We report a preclinical safety study
of a 7 French (F) system in a domestic swine model.
Methods: The 7F device was used to treat the renal arteries of 20 pigs, with over-
lapping treatments in the proximal 12 mm to mimic clinical balloon overlap. Each
histopathology cohort (30 & 90 day follow-up) had 4 RF-treated and 3 sham-treated
(no RF energy delivered) pigs and response of artery and surrounding nerves to
bilateral treatment was examined (28 arteries). Scanning electron microscopy was used
to examine the renal artery ﬂow surface for endothelialization, with unilateral whole
artery treatment with proximal overlap: RF on one side and sham on the other (3 pigs/
cohort; 12 arteries). Treatment duration was 30 seconds. Animals received 2 to 3
treatments per artery depending on artery length. Histology on all 40 kidneys and
assessment for non-target injury was undertaken in all 20 pigs.
Results: Renal artery injury was transmural and segmental, with variable percentages
of the circumference (<10% to >90%, typically 30-50%) demonstrating overlying
nerve injury and associated segmental neointimal hyperplasia. No increase in thermal
injury was observed in overlapped vs single-treatment segments. At 30 days, “islands”
of necrotic media remained, but at 90 days healing was essentially complete with
mature replacement ﬁbrosis. Inﬂammatory activity was mild at 30 days and minimal by
90 days. Maximum lumen stenosis (all sections, both time points) was 17.7%, he-
modynamically trivial, and typically <10%. Endothelialization was focally incomplete
at 30 days, but completely conﬂuent at 90 days. Sham-treated arteries showed only
mild focal mechanical injury, which was also seen with thermal treatment. Kidney
histology demonstrated no injury, and there was no injury to renal veins, ureters,
adrenal glands, psoas muscles, peritoneum or intestines.
Conclusion: Safety of the Boston Scientiﬁc Vessix renal denervation system in 7F
conﬁguration was demonstrated for both single and overlap treatment.
Technology
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Poor Outcome in Patients Requiring Intra-Aortic Balloon Pump Reinsertion in
Cardiogenic Shock
Edward Howard, Jill Steiner, Rebecca Torguson, Julio Panza, Howard Cooper
MedStar Washington Hospital Center, Washington, DC
Background: Intra-aortic balloon pumping (IABP) is the most frequently utilized
form of temporary mechanical support in cardiogenic shock. Withdrawal of IABP
support occasionally precipitates hemodynamic compromise or collapse such that
IABP reinsertion is considered or performed. The outcome of patients undergoing
IABP reinsertion has not been formally studied.
Methods: Using the MedStar Washington Hospital Center Cardiac Care Unit
(CCU) database, we identiﬁed a population of patients presenting with cardiogenic
shock who required IABP reinsertion after failed wean. As a control we identiﬁed a
matched population of patients who had received only a single IABP for cardiogenic
shock. The primary outcome investigated was in-hospital mortality. Secondary out-
comes included the utilization of other temporary or permanent methods of cardiac
support, transplant, and discharge to hospice and a composite thereof.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 2 , S u p p l S , 2 0 1 4 S51Results: 20 subjects were eligible for inclusion in the study and 38 matched controls
were identiﬁed, with both groups evenly matched at baseline. The incidence of in-
hospital mortality was 70% in the reinsertion group and 31.2% in the controls (OR
2.2; p¼0.005). The composite secondary endpoint of death, LVAD insertion during
index hospitalization or discharge to hospice was also signiﬁcantly higher in the
reinsertion group than the controls (85% vs 42.1%; OR¼2.0; p¼0.002). We also
performed multivariate analysis and found that use of multiple IABPs was indepen-
dently predictive of in-hospital mortality (p<0.05).
Conclusion: Reinsertion of IABP after failure of initial wean is associated with
extremely high in-hospital mortality and independently predicts mortality in patients
with cardiogenic shock. This study supports the notion that if IABP weaning or
removal is unsuccessful, alternative and more aggressive regimens of short or even
long-term mechanical support be considered where appropriate such as surgical
LVAD or extra-corporeal membrane oxygenation (ECMO).VALVE & STRUCTURAL HEART
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Should a New Bleeding Risk Score be Developed to Account for the Added Risks in
Patients With Moderate or Severe Aortic Stenosis Who Undergo Percutaneous
Coronary Intervention?
Christopher Huffman, Rebecca Torguson, Fang Chen, Augusto Pichard, Lowell Satler,
Kenneth Kent, William Suddath, Ron Waksman
Medstar Washington Hospital Center, Washington, DC
Background: Aortic stenosis (AS) is associated with an increased risk of bleeding, but
little is known about the risk of bleeding during percutaneous coronary intervention
(PCI) in patients with AS. In the age of transcatheter aortic valve replacement
(TAVR), patients with AS frequently undergo PCI prior to TAVR; therefore, un-
derstanding whether these patients have a higher risk of bleeding is critical.
Methods: This retrospective study included 7,926 patients who underwent PCI from
March 18, 2004 to January 31, 2013. Patients were categorized according to the
presence of hemodynamically signiﬁcant AS: Moderate/Severe AS (n¼354) and Mild/
No AS (n¼7,572). The National Cardiovascular Data Registry (NCDR) deﬁnition of
a bleeding event (requiring transfusion, prolonged hospital stay, or drop in hemoglobin
>3.0 mg/dL) was used as the primary outcome, and the NCDR PCI Bleeding Risk
Score (risk score components in Table) was used to control for the underlying bleeding
risk due to baseline patient characteristics.
Results: Logistic regression showed that the NCDR PCI Bleeding Risk Score did
predict bleeding outcomes in these patients. Patients with AS had signiﬁcantly higher
NCDR PCI Bleeding Risk Scores as well as higher rates of bleeding events (Table).
There was not, however, an independent association between AS and bleeding out-
comes. The addition of AS to the risk score using Net Reclassiﬁcation Improvement
did not enhance the model’s ability to predict bleeding (p¼0.71).Moderate/Severe
ASMild/No
AS p ValueAge, years 79.9 10.98 65.06 12.23 < 0.001Female Gender, % 45.5 35.9 < 0.001Congestive Heart Failure, % 37.9 16.7 < 0.001Congestive Heart Failure Class III or
IV, %20.7 8.4 < 0.001History of PCI, % 27.5 30.6 0.212History of Peripheral Vascular
Disease, %27.9 16.1 < 0.001Chronic Renal Insufﬁciency, % 37.7 18.0 < 0.001Myocardial Infarction This
Admission, %27.8 38.1 < 0.001Cardiogenic Shock, % 2.1 3.5 0.158NCDR PCI Bleeding Score 18.71 7.55 12.97 7.56 < 0.001Hematocrit Drop > 15, % 4.1 2.1 0.011Hematoma, % 5.8 2.2 < 0.001NCDR Bleeding Event, % 10.3 4.9 < 0.001Conclusions: These data suggest that the NCDR PCI Bleeding Risk Score appro-
priately adjusts for bleeding risks in patients with moderate or severe AS. As more
patients with increasingly severe comorbidities undergo TAVR evaluation, with some
requiring PCI, this risk score may need further adjustment to account for the
increasingly complex and frail nature of the TAVR population.
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A Comparison of Post Implant Aortic Valve Gradient of Transcatheter and Surgical
Tissue Valves in Symptomatic Severe Aortic Stenosis
Mohammed Salem, Kamran Baig, Robert Henderson, Thomas Mathew
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Background: The design and ﬂow proﬁle of transcatheter aortic valve (TAVI) is
different from surgical prosthetic valve. We compared the post implantation echo-
cardiographic aortic valve gradient of patients undergoing TAVI using Edwards
Sapien in our institution to that of surgically implanted bioprosthetic valves (SAVR)
using St Jude Epic, Hancock and Mitrﬂow valves during the same period.
Methods: Consecutive patients who underwent TAVI between January 2010 and
May 2011 were included. Patients who underwent SAVR for native aortic stenosis
(AS) were identiﬁed from our database and patients who completed at least one follow
up transthoracic echocardiogram (TTE) were included for ﬁnal analysis. The last
performed TTE was included for analysis in both groups.
Results: Thirty six patients underwent TAVI valves between January 2010 and May
2011 and TTE data were available for 34 patients who were included for ﬁnal analysis.
Seventy two patients underwent SAVR with a bioprosthetic valve during the same
period and TTE data were available for 30 patients who were included for ﬁnal
analysis. Mean age (TAVI 83.4  5.8 vs SAVR 76.3  5.2 years, p <0.001) and
logistic Euroscore (TAVI 26.4  12.5 vs SAVR 8.4  5.2, p <0.001) were signiﬁ-
cantly higher in the TAVI group but the body surface area an important determinant
of echo gradient was similar in both groups (TAVI 1.8  0.23 vs SAVR 1.83  0.24,
p¼0.34). The pre procedure peak aortic valve gradients (TAVI 85.2  20.1 vs SAVR
83.0  22.3, p¼0.67) were similar in both groups but the mean aortic valve gradients
(TAVI 53.2  14.46 vs SAVR 45.8  12.8, p <0.05) were signiﬁcantly higher in
the TAVI group. The post implant peak gradients (TAVI 21.09  11.5 vs SAVR
30.24  10.6, p <0.005) and mean gradients (TAVI 12.66  7.9 vs SAVR
